NR4A1 and breast cancer: Luminal breast cancers, which represent the largest proportion of all breast tumors (∼70–75%) and have a more favorable prognosis compared to the other molecular subtypes, benefit from the use of targeted endocrine therapies due to the expression of hormone receptors.